Stem Cell-Derived Organoids for Cancer Therapy: Precision Medicine and Drug Selection

Area of Science:

• Biomedical Engineering
• Oncology
• Stem Cell Biology

Background:

• Cancer research urgently needs better preclinical models beyond 2D cultures and animal systems.
• Three-dimensional (3D) organoid technology offers patient-specific mini-organ models that mimic primary tumors.
• Organoids preserve key stem cell pathways (Wnt, Notch, Hippo) for disease modeling and drug screening.

Purpose of the Study:

• To review organoid systems, including patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids, as 'avatars' for personalized cancer therapeutics.
• To highlight the role of organoids in functional precision medicine, citing >90% predictive accuracy in clinical studies.
• To discuss organoids' potential in regenerative oncology for targeting cancer stem cells (CSCs) and enhancing tissue repair.

Main Methods:

• Review of patient-derived organoids (PDOs) and induced pluripotent stem cell (iPSC)-derived organoids.
• Analysis of organoid applications in disease modeling, high-throughput drug screening, and regenerative oncology.
• Examination of advancements in organoid-on-a-chip, 3D bioprinting, and AI for addressing challenges like vascularization and immune integration.

Main Results:

• Organoids accurately recapitulate tumor genetics, phenotype, and architecture.
• Organoids demonstrate high predictive accuracy (>90%) in clinical studies, validating their use in precision medicine.
• Emerging technologies like organoid-on-a-chip and AI integration are enhancing organoid capabilities.

Conclusions:

• Organoids provide a fully humanized platform for preclinical cancer modeling and clinical applications.
• Organoid technology is poised to advance personalized cancer therapeutics with improved predictive and translational power.
• Standardized, GMP-compliant platforms and regulatory initiatives support the integration of organoids into cancer research and therapy.